Archives: Agenda

As an industry, it is essential to continuously bring on new sites and new physicians, ensuring they do not become a one-and-done site or Principal Investigator (PI). Therefore, Endo will share strategies to help sponsors find effective ways to guide naive sites on where to start in clinical research and support them every step of the way, from pre-study visits to study closure. Part of the strategies include the inclusion of a Site Relationship Manager role at Endo.

• Optimize Employ Effort
• Minimize Waste and Risk
• Appreciate Significant Savings
• Sustainably Friendly

• Weighing up pros and cons of different outsourcing models: which is best for your trial?
• When is mixing and matching better than fully outsourcing or keeping trials fully in house?
• Developing an outsourcing strategy as a small to medium sized biotech with limited resources
• Why is FSP becoming a popular choice among sponsor companies and how can this support meeting trial timelines?
• How do strategic alliances impact this decision?

This session will address challenges in financial services, such as regulatory pressure, customer expectations, and competition, and highlight trends like Explainable AI (XAI) and responsible AI. It will demonstrate how EdgeVerve’s AI First Platform is designed to tackle these challenges, empowering financial institutions to achieve their transformation goals through

• AI-powered operational efficiency and automation.
• Enhancing customer experience and fraud detection.
• Data-driven risk and innovation decisions
• Customer success stories showcasing the platform’s impact.

Join to understand how the platform’s role as a strategic partner for financial institutions in an AI-driven future.

In a landscape where the expectations for Generative AI are rapidly evolving, this session will delve into the critical role Graph technology plays in advancing Retrieval-Augmented Generation (RAG). As recognized by Gartner and other leading analysts, Graphs are now pivotal in enhancing the accuracy and reliability of Generative AI.
Attendees will learn how the integration of Graph technology with RAG not only addresses the inherent limitations of traditional models but also establishes a solid foundation for developing enterprise-grade Generative AI solutions that are precise, trustworthy, and capable of meeting the demands of today’s data-driven world in highly regulated industries.

• Overviewing ethical concerns of implementing LLMs, GenAI, models, transparency, and responsibility
• To what extent is AI considered unethical?
• Exploring the significance of AI safety and tackling risks of hallucinations in ethical audits
• Who has the answer to efficiently showcase emissions, ethics and ESGs reports supported by AI?
• Discussing potential techniques to enhance ethical data analysis and reporting using AI

To maximise the benefits of AI, business leaders must ensure investments are well-placed to drive value and competitive differentiation. Given its budgetary, security, and ethical implications, AI has rapidly become a board-level priority. It’s essential to reposition AI from being solely an IT responsibility to a collaborative effort across the entire organisation.

This session will explore the successful business outcomes that a unified strategy around AI adoption can deliver for organisations, particularly how to accelerate their AI journeys from proof of concept to production while also reducing risk.